Trial Profile
Phase I/II Study of Autologous Tumor Cell Vaccination Using Metronomic Cyclophosphamide, 3-Dimensional Conformal Radiotherapy, Intra/Peri-Tumor Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Poly ICLC Boosting in Patients With Unresectable, Recurrent, or Metastatic Cancers in the Liver (Hepatoma, Cholangiocarcinoma, Neuroendocrine, Breast, Colon, Gastric, and Esophageal Cancer).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Aug 2015
Price :
$35
*
At a glance
- Drugs Poly ICLC (Primary) ; Poly ICLC (Primary) ; Cyclophosphamide
- Indications Advanced breast cancer; Cholangiocarcinoma; Colon cancer; Gastric cancer; Liver cancer; Liver metastases; Malignant melanoma; Neuroendocrine carcinoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- 11 Jan 2014 Endpoints amended as reported by ClinicalTrials.gov
- 11 Jan 2014 Planned End Date changed from 1 Oct 2009 to 1 Jul 2014 as reported by ClinicalTrials.gov
- 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).